|
US9017A
(en)
|
|
1852-06-15 |
|
Cast-iron cab-wheel |
|
US674A
(en)
|
|
1838-04-05 |
|
Draft-box eob steam-engines |
|
US3687808A
(en)
|
1969-08-14 |
1972-08-29 |
Univ Leland Stanford Junior |
Synthetic polynucleotides
|
|
US4034074A
(en)
|
1974-09-19 |
1977-07-05 |
The Board Of Trustees Of Leland Stanford Junior University |
Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
|
|
US4036945A
(en)
|
1976-05-03 |
1977-07-19 |
The Massachusetts General Hospital |
Composition and method for determining the size and location of myocardial infarcts
|
|
US4098876A
(en)
|
1976-10-26 |
1978-07-04 |
Corning Glass Works |
Reverse sandwich immunoassay
|
|
US4233402A
(en)
|
1978-04-05 |
1980-11-11 |
Syva Company |
Reagents and method employing channeling
|
|
US4272398A
(en)
|
1978-08-17 |
1981-06-09 |
The United States Of America As Represented By The Secretary Of Agriculture |
Microencapsulation process
|
|
US4257774A
(en)
|
1979-07-16 |
1981-03-24 |
Meloy Laboratories, Inc. |
Intercalation inhibition assay for compounds that interact with DNA or RNA
|
|
US4331647A
(en)
|
1980-03-03 |
1982-05-25 |
Goldenberg Milton David |
Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
|
|
US4376110A
(en)
|
1980-08-04 |
1983-03-08 |
Hybritech, Incorporated |
Immunometric assays using monoclonal antibodies
|
|
US4469863A
(en)
|
1980-11-12 |
1984-09-04 |
Ts O Paul O P |
Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
|
|
US4769330A
(en)
|
1981-12-24 |
1988-09-06 |
Health Research, Incorporated |
Modified vaccinia virus and methods for making and using the same
|
|
US5155020A
(en)
|
1989-03-08 |
1992-10-13 |
Health Research Inc. |
Recombinant poxvirus host range selection system
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4650764A
(en)
|
1983-04-12 |
1987-03-17 |
Wisconsin Alumni Research Foundation |
Helper cell
|
|
JPS61134325A
(ja)
|
1984-12-04 |
1986-06-21 |
Teijin Ltd |
ハイブリツド抗体遺伝子の発現方法
|
|
US5235033A
(en)
|
1985-03-15 |
1993-08-10 |
Anti-Gene Development Group |
Alpha-morpholino ribonucleoside derivatives and polymers thereof
|
|
US5618920A
(en)
|
1985-11-01 |
1997-04-08 |
Xoma Corporation |
Modular assembly of antibody genes, antibodies prepared thereby and use
|
|
US4861719A
(en)
|
1986-04-25 |
1989-08-29 |
Fred Hutchinson Cancer Research Center |
DNA constructs for retrovirus packaging cell lines
|
|
US4925673A
(en)
|
1986-08-18 |
1990-05-15 |
Clinical Technologies Associates, Inc. |
Delivery systems for pharmacological agents encapsulated with proteinoids
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US4987071A
(en)
|
1986-12-03 |
1991-01-22 |
University Patents, Inc. |
RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
|
|
US4980289A
(en)
|
1987-04-27 |
1990-12-25 |
Wisconsin Alumni Research Foundation |
Promoter deficient retroviral vector
|
|
US4861627A
(en)
|
1987-05-01 |
1989-08-29 |
Massachusetts Institute Of Technology |
Preparation of multiwall polymeric microcapsules
|
|
US5254678A
(en)
|
1987-12-15 |
1993-10-19 |
Gene Shears Pty. Limited |
Ribozymes
|
|
ES2092468T3
(es)
|
1988-01-22 |
1996-12-01 |
Zymogenetics Inc |
Metodos para producir analogos de receptores secretados.
|
|
US5750375A
(en)
|
1988-01-22 |
1998-05-12 |
Zymogenetics, Inc. |
Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
|
|
US5567584A
(en)
|
1988-01-22 |
1996-10-22 |
Zymogenetics, Inc. |
Methods of using biologically active dimerized polypeptide fusions to detect PDGF
|
|
US6018026A
(en)
|
1988-01-22 |
2000-01-25 |
Zymogenetics, Inc. |
Biologically active dimerized and multimerized polypeptide fusions
|
|
US5278056A
(en)
|
1988-02-05 |
1994-01-11 |
The Trustees Of Columbia University In The City Of New York |
Retroviral packaging cell lines and process of using same
|
|
US5750666A
(en)
|
1988-05-26 |
1998-05-12 |
Competitve Technologies, Inc. |
Polynucleotide phosphorodithioate compounds
|
|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
|
IL162181A
(en)
|
1988-12-28 |
2006-04-10 |
Pdl Biopharma Inc |
A method of producing humanized immunoglubulin, and polynucleotides encoding the same
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5124263A
(en)
|
1989-01-12 |
1992-06-23 |
Wisconsin Alumni Research Foundation |
Recombination resistant retroviral helper cell and products produced thereby
|
|
US5225538A
(en)
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
|
US5225336A
(en)
|
1989-03-08 |
1993-07-06 |
Health Research Incorporated |
Recombinant poxvirus host range selection system
|
|
US5175099A
(en)
|
1989-05-17 |
1992-12-29 |
Research Corporation Technologies, Inc. |
Retrovirus-mediated secretion of recombinant products
|
|
US5240846A
(en)
|
1989-08-22 |
1993-08-31 |
The Regents Of The University Of Michigan |
Gene therapy vector for cystic fibrosis
|
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
EP1690935A3
(en)
|
1990-01-12 |
2008-07-30 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
DE69030172T2
(de)
|
1990-01-26 |
1997-06-19 |
Immunomedics Inc |
Impfstoffe gegen Krebs und Infektionskrankheiten
|
|
US5204243A
(en)
|
1990-02-14 |
1993-04-20 |
Health Research Incorporated |
Recombinant poxvirus internal cores
|
|
US5214136A
(en)
|
1990-02-20 |
1993-05-25 |
Gilead Sciences, Inc. |
Anthraquinone-derivatives oligonucleotides
|
|
US6641809B1
(en)
|
1990-03-26 |
2003-11-04 |
Bristol-Myers Squibb Company |
Method of regulating cellular processes mediated by B7 and CD28
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
WO1992000092A1
(en)
|
1990-07-02 |
1992-01-09 |
Bristol-Myers Squibb Company |
Ligand for cd28 receptor on b cells and methods
|
|
ES2139598T3
(es)
|
1990-07-10 |
2000-02-16 |
Medical Res Council |
Procedimientos para la produccion de miembros de parejas de union especifica.
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
US5218105A
(en)
|
1990-07-27 |
1993-06-08 |
Isis Pharmaceuticals |
Polyamine conjugated oligonucleotides
|
|
WO1992005186A1
(en)
|
1990-09-20 |
1992-04-02 |
Gilead Sciences |
Modified internucleoside linkages
|
|
US5296347A
(en)
|
1991-02-08 |
1994-03-22 |
Ciba Corning Diagnostics Corp. |
Bridge immunoassay
|
|
AU658396B2
(en)
|
1991-03-06 |
1995-04-13 |
Merck Patent Gesellschaft Mit Beschrankter Haftung |
Humanized and chimeric monoclonal antibodies
|
|
JP3507486B2
(ja)
|
1991-03-15 |
2004-03-15 |
アムジエン・インコーポレーテツド |
顆粒球コロニー刺激因子の肺内投与
|
|
WO1993001222A1
(fr)
|
1991-07-03 |
1993-01-21 |
Kanebo, Ltd. |
Elastomere de polyurethane thermoplastique, procede et dispositif de production, et fibre elastique realisee a partir de cet elastomere
|
|
CA2078539C
(en)
|
1991-09-18 |
2005-08-02 |
Kenya Shitara |
Process for producing humanized chimera antibody
|
|
ES2136092T3
(es)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
Procedimientos para la produccion de anticuerpos humanizados.
|
|
GB9125979D0
(en)
|
1991-12-06 |
1992-02-05 |
Wellcome Found |
Antibody
|
|
US5863537A
(en)
|
1992-02-19 |
1999-01-26 |
Schering Corporation |
Humanized monoclonal antibodies against human interleukin-4
|
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
|
AU6827094A
(en)
|
1993-05-07 |
1994-12-12 |
Immunex Corporation |
Cytokine designated 4-1bb ligand and human receptor that binds thereto
|
|
US7211259B1
(en)
|
1993-05-07 |
2007-05-01 |
Immunex Corporation |
4-1BB polypeptides and DNA encoding 4-1BB polypeptides
|
|
US5942607A
(en)
|
1993-07-26 |
1999-08-24 |
Dana-Farber Cancer Institute |
B7-2: a CTLA4/CD28 ligand
|
|
US5861310A
(en)
|
1993-11-03 |
1999-01-19 |
Dana-Farber Cancer Institute |
Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
|
|
WO1995005464A1
(en)
|
1993-08-16 |
1995-02-23 |
Arch Development Corporation |
B7-2: ctla4/cd28 counter receptor
|
|
CN1135181A
(zh)
|
1993-09-14 |
1996-11-06 |
Cytel有限公司 |
使用泛dr结合肽改变免疫应答
|
|
CA2172165C
(en)
|
1993-09-16 |
2003-12-02 |
Byoung S. Kwon |
Human receptor h4-1bb
|
|
US5451569A
(en)
|
1994-04-19 |
1995-09-19 |
Hong Kong University Of Science And Technology R & D Corporation Limited |
Pulmonary drug delivery system
|
|
US5972703A
(en)
|
1994-08-12 |
1999-10-26 |
The Regents Of The University Of Michigan |
Bone precursor cells: compositions and methods
|
|
US5705154A
(en)
|
1995-03-08 |
1998-01-06 |
Schering Corporation |
Humanized monoclonal antibodies against human interleukin-4
|
|
AU5369996A
(en)
|
1995-03-23 |
1996-10-08 |
Indiana University Foundation |
Monoclonal antibody against human receptor protein 4-1bb and methods of its use for treatment of diseases
|
|
DE69624436T2
(de)
|
1995-04-08 |
2003-08-28 |
Lg Chemical Ltd., Seoul/Soul |
Humaner 4-1bb spezifischer humaner antikörper und diesen produzierende zellinie
|
|
US5675848A
(en)
|
1995-10-18 |
1997-10-14 |
Mallinckrodt Medical, Inc. |
Inflatable blanket having perforations of different sizes
|
|
NZ322175A
(en)
|
1995-11-10 |
1999-02-25 |
Elan Corp Plc |
Peptides which enhance transport across tissues and methods of identifying the same
|
|
EP0871747A1
(en)
|
1996-01-02 |
1998-10-21 |
Chiron Viagene, Inc. |
Immunostimulation mediated by gene-modified dendritic cells
|
|
US5874240A
(en)
|
1996-03-15 |
1999-02-23 |
Human Genome Sciences, Inc. |
Human 4-1BB receptor splicing variant
|
|
ATE230801T1
(de)
|
1996-10-03 |
2003-01-15 |
Canon Kk |
Verfahren zur detektion von zielnukleinsäure, verfahren zu ihrer quantifizierung und pyrylium- verbindungen zur chemilumineszenz-analyse
|
|
IL129138A0
(en)
|
1996-10-11 |
2000-02-17 |
Bristol Myers Squibb Co |
Methods and compositions for immunomodulation
|
|
DE69739105D1
(de)
|
1996-11-20 |
2008-12-24 |
Univ Yale |
Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulation
|
|
AUPO390396A0
(en)
|
1996-11-29 |
1996-12-19 |
Csl Limited |
Novel promiscuous T helper cell epitopes
|
|
EP1012275A1
(en)
|
1997-01-31 |
2000-06-28 |
University Of Rochester |
Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
|
|
AU6534898A
(en)
|
1997-02-14 |
1998-09-08 |
E.I. Du Pont De Nemours And Company |
Detection of double-stranded dna in a homogeneous solution
|
|
US7411051B2
(en)
|
1997-03-07 |
2008-08-12 |
Human Genome Sciences, Inc. |
Antibodies to HDPPA04 polypeptide
|
|
US20070224663A1
(en)
|
1997-03-07 |
2007-09-27 |
Human Genome Sciences, Inc. |
Human Secreted Proteins
|
|
US20060223088A1
(en)
|
1997-03-07 |
2006-10-05 |
Rosen Craig A |
Human secreted proteins
|
|
WO2001034629A1
(en)
|
1999-11-12 |
2001-05-17 |
Human Genome Sciences, Inc. |
21 human secreted proteins
|
|
US7368531B2
(en)
|
1997-03-07 |
2008-05-06 |
Human Genome Sciences, Inc. |
Human secreted proteins
|
|
US7064193B1
(en)
|
1997-09-17 |
2006-06-20 |
The Walter And Eliza Hall Institute Of Medical Research |
Therapeutic molecules
|
|
WO1999064597A1
(en)
|
1998-06-10 |
1999-12-16 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
β2 MICROGLOBULIN FUSION PROTEINS AND HIGH AFFINITY VARIANTS
|
|
WO2000026342A1
(en)
|
1998-10-30 |
2000-05-11 |
Northwestern University |
Method of interfering with cell proliferation
|
|
KR20000034847A
(ko)
|
1998-11-17 |
2000-06-26 |
성재갑 |
인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물
|
|
US6734172B2
(en)
|
1998-11-18 |
2004-05-11 |
Pacific Northwest Research Institute |
Surface receptor antigen vaccines
|
|
WO2000041508A2
(en)
|
1999-01-15 |
2000-07-20 |
Mount Sinai School Of Medicine Of The City University Of New York |
Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines
|
|
WO2000055375A1
(en)
|
1999-03-17 |
2000-09-21 |
Alphagene, Inc. |
Secreted proteins and polynucleotides encoding them
|
|
ATE399793T1
(de)
|
1999-04-02 |
2008-07-15 |
Corixa Corp |
Verbindungen und verfahren für therapie und diagnose von lungenkrebs
|
|
EP1074617A3
(en)
|
1999-07-29 |
2004-04-21 |
Research Association for Biotechnology |
Primers for synthesising full-length cDNA and their use
|
|
US6423885B1
(en)
|
1999-08-13 |
2002-07-23 |
Commonwealth Scientific And Industrial Research Organization (Csiro) |
Methods for obtaining modified phenotypes in plant cells
|
|
US20020177551A1
(en)
|
2000-05-31 |
2002-11-28 |
Terman David S. |
Compositions and methods for treatment of neoplastic disease
|
|
US6803192B1
(en)
|
1999-11-30 |
2004-10-12 |
Mayo Foundation For Medical Education And Research |
B7-H1, a novel immunoregulatory molecule
|
|
CA3016482A1
(en)
|
1999-11-30 |
2001-06-07 |
Mayo Foundation For Medical Education And Research |
B7-h1, a novel immunoregulatory molecule
|
|
US7074408B2
(en)
|
2000-02-25 |
2006-07-11 |
Immunex Corporation |
Use of integrin antagonists to inhibit angiogenesis
|
|
AU4592601A
(en)
|
2000-03-21 |
2001-10-03 |
Millennium Predictive Medicine |
Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer
|
|
US6926898B2
(en)
|
2000-04-12 |
2005-08-09 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
|
US6965018B2
(en)
|
2000-06-06 |
2005-11-15 |
Bristol-Myers Squibb Company |
Antibodies directed to B7-related polypeptide, BSL-2
|
|
WO2002000692A2
(en)
|
2000-06-28 |
2002-01-03 |
Genetics Institute, Llc. |
Pd-l2 molecules: pd-1 ligands and uses therefor
|
|
EP1301524A1
(en)
|
2000-06-30 |
2003-04-16 |
Human Genome Sciences, Inc. |
B7-like polynucleotides, polypeptides, and antibodies
|
|
AU7224801A
(en)
|
2000-07-05 |
2002-01-14 |
Vogue Pool Products |
Above ground swimming pool support structure
|
|
US20020076409A1
(en)
|
2000-07-12 |
2002-06-20 |
March Carl J. |
Method for treating cancer
|
|
US6635750B1
(en)
|
2000-07-20 |
2003-10-21 |
Millennium Pharmaceuticals, Inc. |
B7-H2 nucleic acids, members of the B7 family
|
|
WO2002010187A1
(en)
|
2000-07-27 |
2002-02-07 |
Mayo Foundation For Medical Education And Research |
B7-h3 and b7-h4, novel immunoregulatory molecules
|
|
EP1326961B1
(en)
|
2000-09-15 |
2007-08-22 |
Ortho-McNeil Pharmaceutical, Inc. |
Compositions and methods for inducing specific cytolytic t cell responses
|
|
CA2422215A1
(en)
|
2000-09-20 |
2002-03-28 |
Amgen Inc. |
B7-like molecules and uses thereof
|
|
WO2002036141A2
(en)
|
2000-11-02 |
2002-05-10 |
Immunex Corporation |
Method of enhancing lymphocyte-mediated immune responses
|
|
US20040209263A1
(en)
|
2000-12-07 |
2004-10-21 |
Clawson Gary A. |
Selection of catalytic nucleic acids targeted to infectious agents
|
|
JP2005508601A
(ja)
|
2000-12-19 |
2005-04-07 |
キュラジェン コーポレイション |
ポリペプチドおよびそれをコードする核酸
|
|
US6773702B2
(en)
|
2000-12-26 |
2004-08-10 |
Oxigene, Inc. |
Use of combretastatin A4 and its prodrugs as an immune enhancing therapy
|
|
US20030180309A1
(en)
|
2001-01-08 |
2003-09-25 |
Baum Peter R. |
Human B7 polypeptides
|
|
JP4368110B2
(ja)
|
2001-01-12 |
2009-11-18 |
エール ユニヴァーシティ |
癌患者の生物学的流体中のサバイビンの検出
|
|
US6743619B1
(en)
|
2001-01-30 |
2004-06-01 |
Nuvelo |
Nucleic acids and polypeptides
|
|
WO2003008583A2
(en)
|
2001-03-02 |
2003-01-30 |
Sagres Discovery |
Novel compositions and methods for cancer
|
|
AR036993A1
(es)
|
2001-04-02 |
2004-10-20 |
Wyeth Corp |
Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
|
|
US20060084794A1
(en)
|
2001-04-12 |
2006-04-20 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
US7794710B2
(en)
|
2001-04-20 |
2010-09-14 |
Mayo Foundation For Medical Education And Research |
Methods of enhancing T cell responsiveness
|
|
US20060276422A1
(en)
|
2001-05-18 |
2006-12-07 |
Nassim Usman |
RNA interference mediated inhibition of B7-H1 gene expression using short interfering nucleic acid (siNA)
|
|
WO2003006632A2
(en)
|
2001-07-12 |
2003-01-23 |
Canvac |
Methods and compisitions for activation human t cells in vitro
|
|
AU2002364935A1
(en)
|
2001-10-09 |
2003-06-23 |
Mayo Foundation For Medical Education And Research |
Enhancement of immune responses by 4-1bb-binding agents
|
|
AU2002337920A1
(en)
|
2001-10-19 |
2003-04-28 |
Zymogenetics, Inc. |
Dimerized growth factor and materials and methods for producing it
|
|
EP1456652A4
(en)
|
2001-11-13 |
2005-11-02 |
Dana Farber Cancer Inst Inc |
IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
|
|
US7164500B2
(en)
|
2002-01-29 |
2007-01-16 |
Hewlett-Packard Development Company, L.P. |
Method and apparatus for the automatic generation of image capture device control marks
|
|
US20060068386A1
(en)
|
2002-03-04 |
2006-03-30 |
Alexei Slesarev |
Complete genome and protein sequence of the hyperthermophile methanopyrus kandleri av19 and monophyly of archael methanogens and methods of use thereof
|
|
US20030223989A1
(en)
|
2002-04-18 |
2003-12-04 |
Pluenneke John D. |
CD137 agonists to treat patients with IgE-mediated conditions
|
|
DE60334303D1
(de)
|
2002-07-03 |
2010-11-04 |
Tasuku Honjo |
Immunpotenzierende zusammensetzungen
|
|
US20040109847A1
(en)
|
2002-07-15 |
2004-06-10 |
Lieping Chen |
Treatment and prophylaxis with 4-1BB-binding agents
|
|
US7432351B1
(en)
|
2002-10-04 |
2008-10-07 |
Mayo Foundation For Medical Education And Research |
B7-H1 variants
|
|
US7449300B2
(en)
|
2002-11-21 |
2008-11-11 |
Mayo Foundation For Medical Education And Research |
Detection of antibodies specific for B7-H1 in subjects with diseases or pathological conditions mediated by activated T cells
|
|
US7563869B2
(en)
|
2003-01-23 |
2009-07-21 |
Ono Pharmaceutical Co., Ltd. |
Substance specific to human PD-1
|
|
US8404681B2
(en)
|
2003-03-24 |
2013-03-26 |
Luitpold Pharmaceuticals, Inc. |
Xanthones, thioxanthones and acridinones as DNA-PK inhibitors
|
|
CA2558811A1
(en)
|
2004-03-08 |
2005-09-22 |
Zymogenetics, Inc. |
Dimeric fusion proteins and materials and methods for producing them
|
|
PL1810026T3
(pl)
|
2004-10-06 |
2018-08-31 |
Mayo Foundation For Medical Education And Research |
B7-H1 i PD-1 w leczeniu raka nerkowokomórkowego
|
|
CN101072578A
(zh)
|
2004-10-29 |
2007-11-14 |
南加州大学 |
用共刺激分子的联合癌症免疫疗法
|
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
|
DK1907000T4
(da)
|
2005-06-08 |
2020-03-30 |
The President And Fellows Of Harvard College |
Fremgangsmåder og sammensætninger til behandling af persisterende HIV-infektioner ved hæmning af reaktionsvejen for programmeret celledød 1 (PD-1).
|
|
US20070231344A1
(en)
|
2005-10-28 |
2007-10-04 |
The Brigham And Women's Hospital, Inc. |
Conjugate vaccines for non-proteinaceous antigens
|
|
US20090215084A1
(en)
|
2006-01-05 |
2009-08-27 |
Mayo Foundation For Medical Education And Research |
B7-h1 and b7-h4 in cancer
|
|
WO2007082144A2
(en)
|
2006-01-05 |
2007-07-19 |
Mayo Foundation For Medical Education And Research |
B7-h1 and survivin in cancer
|
|
KR101395515B1
(ko)
|
2006-02-08 |
2014-05-14 |
모르포테크, 인크. |
항원성 gm-csf 펩티드 및 gm-csf에 대한 항체
|
|
US20100055116A1
(en)
*
|
2006-04-13 |
2010-03-04 |
Liou Hsiou-Chi |
Methods and Compositions for Targeting c-Rel
|
|
WO2007124361A2
(en)
|
2006-04-20 |
2007-11-01 |
Mayo Foundation For Medical Education And Research |
Soluble b7-h1
|
|
AU2007252295B2
(en)
|
2006-05-19 |
2013-07-25 |
Central Adelaide Local Health Network Incorporated |
Selective modulation of receptor signalling
|
|
JP2010504356A
(ja)
|
2006-09-20 |
2010-02-12 |
ザ ジョンズ ホプキンス ユニバーシティー |
抗b7−h1抗体を用いた癌及び感染性疾患の組合せ療法
|
|
WO2008037080A1
(en)
|
2006-09-29 |
2008-04-03 |
Universite De Montreal |
Methods and compositions for immune response modulation and uses thereof
|
|
US20080206241A1
(en)
|
2006-11-21 |
2008-08-28 |
Kalobios Pharmaceuticals Inc. |
Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist
|
|
CA2673870A1
(en)
|
2006-12-27 |
2008-07-10 |
Emory University |
Compositions and methods for the treatment of infections and tumors
|
|
CN101784564B
(zh)
|
2007-07-13 |
2014-07-02 |
约翰霍普金斯大学 |
B7-dc变体
|
|
EP2578677A1
(en)
|
2007-08-09 |
2013-04-10 |
Genzyme Corporation |
Method of treating autoimmune disease with mesenchymal stem cells
|
|
TW200918553A
(en)
|
2007-09-18 |
2009-05-01 |
Amgen Inc |
Human GM-CSF antigen binding proteins
|
|
WO2009089149A1
(en)
|
2008-01-03 |
2009-07-16 |
The Johns Hopkins University |
B7-h1 (cd274) antagonists induce apoptosis of tumor cells
|
|
US20110020325A1
(en)
|
2008-02-29 |
2011-01-27 |
Kwon Eugene D |
Methods for reducing granulomatous inflammation
|
|
US20090226435A1
(en)
|
2008-03-08 |
2009-09-10 |
Sanjay Khare |
Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
|
|
KR101824512B1
(ko)
|
2008-04-28 |
2018-02-02 |
휴머니건, 아이엔씨. |
과립구-대식세포 콜로니 자극 인자에 대한 항체
|
|
WO2010098788A2
(en)
|
2008-08-25 |
2010-09-02 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
|
EA201500417A1
(ru)
|
2008-08-25 |
2015-11-30 |
Эмплиммьюн, Инк. |
Композиции антагонистов pd-1 и способы применения
|
|
WO2010033913A1
(en)
|
2008-09-22 |
2010-03-25 |
Icb International, Inc. |
Antibodies, analogs and uses thereof
|
|
US8889124B2
(en)
|
2008-09-25 |
2014-11-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Tolerogenic populations of dendritic cells
|
|
MX2011005691A
(es)
|
2008-11-28 |
2011-07-20 |
Univ Emory |
Metodos para el tratamiento de infecciones y tumores.
|
|
US8577949B2
(en)
|
2009-07-07 |
2013-11-05 |
L-3 Communications Integrated Systems, L.P. |
System for conjugate gradient linear iterative solvers
|
|
EP3279215B1
(en)
|
2009-11-24 |
2020-02-12 |
MedImmune Limited |
Targeted binding agents against b7-h1
|
|
EP2504028A4
(en)
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
|
|
PT2816112T
(pt)
|
2009-12-10 |
2018-11-20 |
Univ Iowa State Res Found Inc |
Modificação do adn modificada pelo efector tal
|
|
US8383405B2
(en)
|
2010-05-31 |
2013-02-26 |
Imperium Biotechnologies, Inc. |
Methods of using ideotypically modulated pharmacoeffectors for selective cell treatment
|
|
US8518409B2
(en)
|
2010-05-31 |
2013-08-27 |
Imperium Biotechnologies, Inc. |
System for selective cell treatment using ideotypically modulated pharmacoeffectors
|
|
US9029340B2
(en)
|
2010-07-22 |
2015-05-12 |
The Johns Hopkins University |
Radiation sensitization agents for prostate cancer
|
|
US20140127814A1
(en)
*
|
2010-08-10 |
2014-05-08 |
Srinivasan Chandrasegaran |
Generation and use of pluripotent stem cells
|
|
EP2975399B1
(en)
|
2010-09-15 |
2022-05-11 |
Almac Diagnostic Services Limited |
Molecular diagnostic test for cancer
|
|
EP2625278A1
(en)
|
2010-10-08 |
2013-08-14 |
Regents of the University of Minnesota |
A method to increase gene targeting frequency
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
EP3628665B1
(en)
|
2011-04-01 |
2022-11-02 |
University of Utah Research Foundation |
Substituted n-phenylpyrimidin-2-amine analogs as inhibitors of the axl kinase
|
|
JP2014527036A
(ja)
|
2011-06-27 |
2014-10-09 |
ザ ジャクソン ラボラトリー |
癌および自己免疫疾患の処置のための方法および組成物
|
|
BR112013033944A2
(pt)
*
|
2011-07-06 |
2017-12-19 |
Morphosys Ag |
combinação sinérgica
|
|
BR112014002353B1
(pt)
|
2011-08-01 |
2022-09-27 |
Genentech, Inc |
Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
|
|
KR101870555B1
(ko)
|
2011-08-23 |
2018-06-22 |
로슈 글리카트 아게 |
T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
|
|
WO2013090552A1
(en)
|
2011-12-13 |
2013-06-20 |
Yale University |
Compositions and methods for reducing ctl exhaustion
|
|
US9534058B2
(en)
|
2012-02-08 |
2017-01-03 |
Abbvie Stemcentrx Llc |
Anti-CD324 monoclonal antibodies and uses thereof
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
PL4019041T3
(pl)
|
2012-07-13 |
2023-05-08 |
The Trustees Of The University Of Pennsylvania |
Kontrola toksyczności wobec aktywności przeciwnowotworowej CAR
|
|
US10131712B2
(en)
|
2012-08-14 |
2018-11-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors
|
|
US20140195216A1
(en)
|
2013-01-08 |
2014-07-10 |
Imperium Biotechnologies, Inc. |
Computational design of ideotypically modulated pharmacoeffectors for selective cell treatment
|
|
SG11201505896YA
(en)
|
2013-02-20 |
2015-09-29 |
Novartis Ag |
Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
|
|
CN104936985A
(zh)
|
2013-02-26 |
2015-09-23 |
罗切格利卡特公司 |
双特异性t细胞活化性抗原结合分子
|
|
US9302005B2
(en)
|
2013-03-14 |
2016-04-05 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
ES2935257T3
(es)
|
2013-03-15 |
2023-03-03 |
Univ Chicago |
Métodos y composiciones relacionadas con la actividad de las células T
|
|
AU2014386824B2
(en)
|
2013-03-15 |
2019-05-09 |
Memorial Sloan-Kettering Cancer Center |
Compositions and methods for immunotherapy
|
|
US9657105B2
(en)
|
2013-03-15 |
2017-05-23 |
City Of Hope |
CD123-specific chimeric antigen receptor redirected T cells and methods of their use
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
CN105073128A
(zh)
|
2013-04-03 |
2015-11-18 |
Ibc药品公司 |
用于诱导对疾病的免疫应答的组合疗法
|
|
WO2014172470A2
(en)
*
|
2013-04-16 |
2014-10-23 |
Whitehead Institute For Biomedical Research |
Methods of mutating, modifying or modulating nucleic acid in a cell or nonhuman mammal
|
|
SI2997141T1
(sl)
|
2013-05-13 |
2023-04-28 |
Cellectis |
CD19 specifični himerni antigenski receptor in njegova uporaba
|
|
JP6687520B2
(ja)
|
2013-07-18 |
2020-04-22 |
トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー |
極めて長い相補性決定領域を有するヒト化抗体
|
|
EP3022304B1
(en)
|
2013-07-19 |
2018-12-26 |
Larix Biosciences LLC |
Methods and compositions for producing double allele knock outs
|
|
EP3470081A1
(en)
|
2013-10-01 |
2019-04-17 |
Mayo Foundation for Medical Education and Research |
Methods for treating cancer in patients with elevated levels of bim
|
|
CN106232625B
(zh)
|
2013-10-01 |
2020-04-24 |
免疫医疗有限公司 |
治疗和诊断过表达α-V-β-6的癌症的方法
|
|
US10202454B2
(en)
|
2013-10-25 |
2019-02-12 |
Dana-Farber Cancer Institute, Inc. |
Anti-PD-L1 monoclonal antibodies and fragments thereof
|
|
EA201690912A1
(ru)
|
2013-11-05 |
2016-10-31 |
Когнейт Биосервисис, Инк. |
Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака
|
|
JP6976058B2
(ja)
|
2013-11-22 |
2021-12-01 |
セレクティスCellectis |
免疫療法のための化学療法薬耐性t細胞を工学的に作製する方法
|
|
CN103641917B
(zh)
|
2013-12-09 |
2015-07-01 |
江苏众红生物工程创药研究院有限公司 |
抗cd26抗体及其应用
|
|
JP6202339B2
(ja)
|
2013-12-19 |
2017-09-27 |
国立研究開発法人国立精神・神経医療研究センター |
GM−CSF産生T細胞制御剤、及びTh1/Th2免疫バランス調節剤
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗pd-l1之人類抗體
|
|
SG10202109752XA
(en)
*
|
2014-04-07 |
2021-10-28 |
Novartis Ag |
Treatment of cancer using anti-cd19 chimeric antigen receptor
|
|
US9730988B2
(en)
|
2014-04-10 |
2017-08-15 |
University Of Iowa Research Foundation |
Parasitic biological agents for treatment and prevention of graft versus host disease
|
|
KR20160145186A
(ko)
|
2014-04-24 |
2016-12-19 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
입양 세포 요법 생성물을 생성하기 위한 유도 만능 줄기 세포의 응용
|
|
US10302653B2
(en)
|
2014-05-22 |
2019-05-28 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti B7-H1 antibodies
|
|
JP6831777B2
(ja)
|
2014-07-21 |
2021-02-17 |
ノバルティス アーゲー |
Cd33キメラ抗原受容体を使用する癌の処置
|
|
BR112017000939A2
(pt)
|
2014-07-21 |
2017-11-14 |
Novartis Ag |
tratamento de câncer usando um receptor antigênico quimérico de cll-1
|
|
US10517875B2
(en)
|
2014-07-23 |
2019-12-31 |
Mayo Foundation for Medical Engineering and Research |
Targeting DNA-PKcs and B7-H1 to treat cancer
|
|
US10335460B2
(en)
|
2014-07-29 |
2019-07-02 |
Novartis Ag |
IL-15 and IL-15Rα heterodimer dose escalation regimens for treating conditions
|
|
EP3712171A1
(en)
|
2014-08-19 |
2020-09-23 |
Novartis AG |
Treatment of cancer using a cd123 chimeric antigen receptor
|
|
BR112017008042A2
(pt)
*
|
2014-10-20 |
2017-12-26 |
Juno Therapeutics Inc |
métodos e composições para dosagem em terapia de célula adotiva
|
|
WO2016073381A1
(en)
*
|
2014-11-03 |
2016-05-12 |
Cerus Corporation |
Compositions and methods for improved car-t cell therapies
|
|
EP3250602A1
(en)
|
2015-01-26 |
2017-12-06 |
Cellectis |
T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
|
|
US20160237407A1
(en)
|
2015-02-17 |
2016-08-18 |
Batu Biologics, Inc. |
Universal donor chimeric antigen receptor cells
|
|
GB201503742D0
(en)
|
2015-03-05 |
2015-04-22 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
MX2017012829A
(es)
|
2015-04-06 |
2018-02-23 |
Regeneron Pharma |
Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos.
|
|
PL3280729T3
(pl)
|
2015-04-08 |
2022-08-22 |
Novartis Ag |
Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
|
|
GB201507111D0
(en)
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
|
CA3172801A1
(en)
|
2015-06-12 |
2016-12-15 |
Lentigen Technology, Inc. |
Method to treat cancer with engineered t-cells
|
|
TWI833684B
(zh)
|
2015-06-25 |
2024-03-01 |
美商生物細胞基因治療有限公司 |
嵌合抗原受體(car)、組合物及其使用方法
|
|
EP4339287A3
(en)
|
2015-07-31 |
2024-05-22 |
Regents Of The University Of Minnesota |
Modified cells and methods of therapy
|
|
WO2017040930A2
(en)
|
2015-09-03 |
2017-03-09 |
The Trustees Of The University Of Pennsylvania |
Biomarkers predictive of cytokine release syndrome
|
|
CA2999070A1
(en)
|
2015-09-17 |
2017-03-23 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
CA2999500A1
(en)
*
|
2015-09-24 |
2017-03-30 |
Editas Medicine, Inc. |
Use of exonucleases to improve crispr/cas-mediated genome editing
|
|
EP3359650A4
(en)
|
2015-10-08 |
2019-03-20 |
Innovative Cellular Therapeutics Co., Ltd. |
ACTIVATION AND EXPANSION OF CELLS
|
|
WO2017066561A2
(en)
|
2015-10-16 |
2017-04-20 |
President And Fellows Of Harvard College |
Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
|
|
WO2017075045A2
(en)
|
2015-10-30 |
2017-05-04 |
Mayo Foundation For Medical Education And Research |
Antibodies to b7-h1
|
|
KR102929174B1
(ko)
|
2015-10-30 |
2026-02-20 |
더 리전츠 오브 더 유니버시티 오브 캘리포니아 |
줄기세포로부터 t-세포를 생산하는 방법 및 상기 t-세포를 이용한 면역치료 방법
|
|
EP3380602A4
(en)
|
2015-11-23 |
2019-09-25 |
Trustees of Boston University |
METHOD AND COMPOSITIONS RELATED TO CHIMERIC ANTIGEN RECEPTORS
|
|
WO2017096331A1
(en)
|
2015-12-04 |
2017-06-08 |
Juno Therapeutics, Inc. |
Methods and compositions related to toxicity associated with cell therapy
|
|
WO2017100587A1
(en)
|
2015-12-09 |
2017-06-15 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting programmed cell death 1 ligand 1 (pd-l1) and methods of use thereof
|
|
WO2017133175A1
(en)
|
2016-02-04 |
2017-08-10 |
Nanjing Legend Biotech Co., Ltd. |
Engineered mammalian cells for cancer therapy
|
|
CN108697798A
(zh)
|
2016-02-16 |
2018-10-23 |
达纳-法伯癌症研究所有限公司 |
免疫疗法组合物及方法
|
|
JP6884155B2
(ja)
|
2016-02-18 |
2021-06-09 |
エンリヴェックス セラピューティクス リミテッド |
癌治療のための併用免疫療法及びサイトカイン制御療法
|
|
US20170274095A1
(en)
|
2016-03-23 |
2017-09-28 |
The Board Of Trustees Of The Leland Stanford Junior University |
Enhanced regulatory t cells targeted to sites of inflammation with chimeric antigen receptors and expressing factors that enhance viability of pancreatic cells
|
|
US20190112380A1
(en)
|
2016-03-29 |
2019-04-18 |
University Of Southern California |
Chimeric antigen receptors targeting cancer
|
|
AU2017240233B2
(en)
|
2016-03-31 |
2022-07-14 |
University Of Southern California |
A highly sensitive and specific luciferase based reporter assay for antigen detection
|
|
WO2017173360A2
(en)
|
2016-03-31 |
2017-10-05 |
Stcube, Inc. |
Combination treatments directed toward programmed death ligand-1 (pd-l1) positive cancers
|
|
JP2019513737A
(ja)
|
2016-04-08 |
2019-05-30 |
ギリアード サイエンシーズ, インコーポレイテッド |
がん、炎症性疾患および自己免疫疾患を処置するための組成物および方法
|
|
EP3452499A2
(en)
|
2016-05-06 |
2019-03-13 |
Juno Therapeutics, Inc. |
Genetically engineered cells and methods of making the same
|
|
TWI822521B
(zh)
|
2016-05-13 |
2023-11-11 |
美商再生元醫藥公司 |
藉由投予pd-1抑制劑治療皮膚癌之方法
|
|
US20180154183A1
(en)
|
2016-06-22 |
2018-06-07 |
Velayudhan Sahadevan |
Normal Tissue Toxicity Reducing Microbeam-Broadbeam Radiotherapy, Skin's Radio-Response Immunotherapy and Mutated Molecular Apheresis Combined Cancer Treatments
|
|
IL263874B2
(en)
|
2016-06-22 |
2025-02-01 |
David Klatzmann |
Genetically modified T lymphocytes
|
|
CN105949323A
(zh)
|
2016-06-24 |
2016-09-21 |
安徽未名细胞治疗有限公司 |
一种EpCAM特异性嵌合抗原受体及其编码基因、应用
|
|
CN109562126A
(zh)
|
2016-06-24 |
2019-04-02 |
美商生物细胞基因治疗有限公司 |
嵌合抗原受体(car)、组合物及其使用方法
|
|
AU2017290119A1
(en)
|
2016-06-28 |
2019-01-24 |
Geneius Biotechnology, Inc. |
T cell compositions for immunotherapy
|
|
GB201612214D0
(en)
|
2016-07-14 |
2016-08-31 |
Univ Oxford Innovation Ltd |
Method
|
|
EP3484455A2
(en)
|
2016-07-15 |
2019-05-22 |
Novartis AG |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
|
WO2018045069A1
(en)
|
2016-08-31 |
2018-03-08 |
Leonardi Anthony |
IMMUNOTHERAPIES COMBINED WITH TNFa SIGNALING MODULATORS
|
|
US20190262399A1
(en)
|
2016-09-07 |
2019-08-29 |
The Broad Institute, Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
US12447213B2
(en)
|
2016-10-07 |
2025-10-21 |
The Broad Institute, Inc. |
Modulation of novel immune checkpoint targets
|
|
EP3525803B1
(en)
|
2016-10-13 |
2022-12-07 |
Juno Therapeutics, Inc. |
Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
|
|
WO2018073391A1
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Targeted gene insertion for improved immune cells therapy
|
|
JP2020517259A
(ja)
|
2017-04-19 |
2020-06-18 |
ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム |
操作された抗原受容体を発現する免疫細胞
|
|
CN110769898A
(zh)
|
2017-06-22 |
2020-02-07 |
南加利福尼亚大学 |
使用嵌合抗原受体工程化自然杀伤细胞作为化学治疗药物运载体的联合癌症疗法
|
|
IL271946B
(en)
|
2017-07-09 |
2022-09-01 |
Biosight Ltd |
Combination cancer therapy
|
|
EP3668899A4
(en)
|
2017-08-18 |
2020-09-02 |
Celdara Medical, LLC |
CELL-BASED THERAPIES TARGETING DISEASE-ASSOCIATED MOLECULAR MEDIATORS OF FIBROTIC, INFLAMMATORY AND AUTOIMMUNE DISEASES
|
|
CN111757744A
(zh)
|
2017-10-02 |
2020-10-09 |
人源股份有限公司 |
使用gm-csf拮抗剂治疗免疫疗法相关毒性的方法
|
|
US10899831B2
(en)
|
2017-10-02 |
2021-01-26 |
Humanigen, Inc. |
Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
|
|
CN107746831B
(zh)
|
2017-11-07 |
2019-04-23 |
南京北恒生物科技有限公司 |
具有化疗药物抗性的通用型cart/tcrt细胞及其构建方法
|
|
WO2019094559A2
(en)
|
2017-11-09 |
2019-05-16 |
The General Hospital Corporation |
Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
|
|
WO2019094727A1
(en)
|
2017-11-10 |
2019-05-16 |
Mayo Foundation For Medical Education And Research |
Methods and materials for assessing and treating cancer
|
|
EP3716988A4
(en)
|
2017-11-29 |
2021-12-15 |
Figene, LLC |
INTERACTION OF FIBROBLASTS AND IMMUNE CELLS FOR THE ACTIVATION AND USE THEREOF
|
|
EP3731860A1
(en)
|
2017-12-29 |
2020-11-04 |
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. |
Compositions and methods for treating autoimmune disease
|
|
CN109608549B
(zh)
|
2017-12-29 |
2022-02-18 |
郑州大学第一附属医院 |
基于人源间皮素抗体的嵌合抗原受体、慢病毒表达载体及其应用
|
|
WO2019136210A1
(en)
|
2018-01-04 |
2019-07-11 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
WO2019178062A1
(en)
|
2018-03-12 |
2019-09-19 |
Mayo Foundation For Medical Education And Research |
Improving anti-pd-1 cancer therapy
|
|
US20210046109A1
(en)
|
2018-03-14 |
2021-02-18 |
The Regents Of The University Of California |
Suppressive Exosomes in Cancer and for Immunosuppression
|
|
WO2019195142A1
(en)
|
2018-04-03 |
2019-10-10 |
The Board Of Trustees Of The Leland Stanford Junior University |
Mesenchymal stem cells comprising a chimeric antigen receptor (car) for treating inflammatory and autoimmune diseases
|
|
WO2019195759A1
(en)
|
2018-04-05 |
2019-10-10 |
Mayo Foundation For Medical Education And Research |
Materials and methods for treating cancer
|
|
EP3773588A4
(en)
|
2018-04-09 |
2022-01-19 |
Mayo Foundation for Medical Education and Research |
METHODS AND MATERIALS FOR THE TREATMENT OF GRAFT VERSUS HOST DISEASES
|
|
WO2019217423A1
(en)
|
2018-05-07 |
2019-11-14 |
The Regents Of The University Of California |
Compositions and methods for modifying regulatory t cells
|
|
US20210214723A1
(en)
|
2018-06-01 |
2021-07-15 |
Mayo Foundation For Medical Education And Research |
Materials and methods for treating cancer
|
|
EP3824075A4
(en)
|
2018-07-17 |
2022-04-20 |
The Regents of The University of California |
CHIMERA ANTIGEN RECEPTOR T-CELLS DERIVED FROM IMMUNOMANIPULATED PLURIPOTENTS STEM CELLS
|
|
EP3849572A4
(en)
|
2018-09-10 |
2022-07-13 |
Humanigen, Inc. |
METHOD OF TREATMENT OF IMMUNOTHERAPY-RELATED TOXICITY USING A GM-CSF ANTAGONIST
|
|
US11419898B2
(en)
|
2018-10-17 |
2022-08-23 |
Senti Biosciences, Inc. |
Combinatorial cancer immunotherapy
|
|
WO2020092455A2
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
|
US12624086B2
(en)
|
2018-10-31 |
2026-05-12 |
Mayo Foundation For Medical Education And Research |
Materials and methods for treating cancer
|
|
US12257286B2
(en)
|
2018-10-31 |
2025-03-25 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
US12264189B2
(en)
|
2018-10-31 |
2025-04-01 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
WO2022203908A1
(en)
|
2018-10-31 |
2022-09-29 |
Humanigen, Inc. |
Materials and methods for treating cancer
|
|
CA3121911A1
(en)
|
2018-12-06 |
2020-06-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
Regulatable cell surface receptors and related compositions and methods
|
|
CA3127669A1
(en)
|
2019-01-07 |
2020-07-16 |
Hunan Siweikang Therapeutics Co. Ltd |
Modified immune cells co-expressing chimeric antigen receptor and il-6 antagonist for reducing toxicity and uses thereof in adoptive cell therapy
|
|
CN109734813B
(zh)
|
2019-01-28 |
2022-06-17 |
广东昭泰体内生物医药科技有限公司 |
一种嵌合抗原受体及其应用
|
|
CN114599398A
(zh)
|
2019-06-03 |
2022-06-07 |
基尼克萨制药有限公司 |
用gm-csf拮抗剂治疗癌症
|
|
CN110747211A
(zh)
|
2019-10-31 |
2020-02-04 |
北京兴元和济生命医学科技有限公司 |
基于crispr的改变基因产物表达的方法及其应用
|
|
CN115297873A
(zh)
|
2019-11-08 |
2022-11-04 |
梅约医学教育与研究基金会 |
利用工程化改造的间充质干细胞治疗炎症和退行性疾病的方法和物质
|
|
EP4065138A4
(en)
|
2019-11-27 |
2024-02-28 |
Board of Regents, The University of Texas System |
LARGE-SCALE COMBINED CAR TRANSDUCTION AND CRISPR GENE EDITING OF MSC CELLS
|
|
EP3964265A1
(en)
|
2020-09-07 |
2022-03-09 |
Fundacion Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz |
Mesenchymal stem cells co-expressing cxcr4 and il-10 and uses thereof
|
|
CN117615786A
(zh)
|
2021-05-07 |
2024-02-27 |
森蒂生物科学公司 |
嵌合抗原受体及其使用方法
|
|
KR20240004680A
(ko)
|
2021-05-07 |
2024-01-11 |
센티 바이오사이언시스, 인코포레이티드 |
키메라 수용체 및 이의 사용 방법
|
|
WO2022266396A1
(en)
|
2021-06-16 |
2022-12-22 |
Senti Biosciences, Inc. |
Armed chimeric receptors and methods of use thereof
|
|
EP4398917A4
(en)
|
2021-09-09 |
2025-01-22 |
Mayo Foundation for Medical Education and Research |
CANCER TREATMENT
|
|
WO2024059641A2
(en)
|
2022-09-13 |
2024-03-21 |
The Regents Of The University Of California |
Gene targets for manipulating t cell behavior
|
|
EP4612278A1
(en)
|
2022-11-01 |
2025-09-10 |
Mayo Foundation for Medical Education and Research |
Treating cancer
|
|
IL320251A
(en)
|
2022-11-02 |
2025-06-01 |
Mayo Found Medical Education & Res |
Engineered mesenchymal stromal cells
|
|
US20250313608A1
(en)
|
2024-04-09 |
2025-10-09 |
Mayo Foundation For Medical Education And Research |
Materials and methods for treating cancer
|